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ABSTRACT
Introduction Improved nutrition is the major proven
benefit of newborn screening programmes for cystic
fibrosis (CF) and is associated with better clinical
outcomes. It was hypothesised that early pulmonary
inflammation and infection in infants with CF is
associated with worse nutrition.
Methods Weight, height and pulmonary inflammation
and infection in bronchoalveolar lavage (BAL) were
assessed shortly after diagnosis in infants with CF and
again at 1, 2 and 3 years of age. Body mass index (BMI)
was expressed as z-scores. Inflammatory cells and
cytokines (interleukin 1b (IL-1b), IL-6, IL-8 and tumour
necrosis factor a (TNFa)), free neutrophil elastase
activity and myeloperoxidase were measured in BAL.
Mixed effects modelling was used to assess longitudinal
associations between pulmonary inflammation,
pulmonary infection (Staphylococcus aureus and
Pseudomonas aeruginosa) and BMI z-score after
adjusting for potential confounding factors.
Results Forty-two infants were studied (16 (38%) male;
39 (93%) pancreatic insufficient); 36 were diagnosed by
newborn screening (at median age 4 weeks) and six by
early clinical diagnosis (meconium ileus). Thirty-one
(74%) received antistaphylococcal antibiotics. More than
two-thirds were asymptomatic at each assessment.
Mean BMI z-scores were 1.5 at diagnosis and 0.5,
0.2 and 0.1 at 1, 2 and 3 years, respectively.
Neutrophil elastase and infection with S aureus were
associated with lower BMI, whereas age (p¼0.01) and
antistaphylococcal antibiotics (p¼0.013) were
associated with increased BMI. On average, each log10
increase in free neutrophil elastase activity was
associated with a 0.43 (95% CI 0.06 to 0.79) reduction in
BMI z-score.
Discussion Early nutritional status is associated with
the underlying pulmonary pathophysiology in CF, and
better understanding of these relationships is required.
Studies are required to assess whether interventions can
decrease pulmonary inflammation and improve nutrition.
Early surveillance will enable such targeted interventions
with the aim of improving these important clinical
outcomes.
INTRODUCTION
Cystic ﬁbrosis (CF) is a common inherited condi-
tion that results in a shortened life span. Outcomes
for those with CF have consistently improved over
the last 40 years such that the median life expec-
tancy is predicted to have reached 50 years for
those born after 2000.1 Much of this improvement
is due to aggressive treatment of pulmonary infec-
tions and closer attention to maintenance of
nutritional status. Many countries have now
incorporated newborn screening programmes for
CF, and attention is focusing on improving quality
and extent of life by earlier intervention in children.
Most of the morbidity and mortality in CF
results from progressive suppurative lung disease.2
Bronchiectasis leads eventually to respiratory
failure. Pulmonary inﬂammation starts early in
infancy in those with CF and is exaggerated in
response to pulmonary infection.3 Structural
changes also occur much earlier in life than previ-
ously thought4 and, even though those diagnosed
by newborn screening appear to have normal lung
function during the ﬁrst 6 months of life,5 bron-
chiectasis can be detected shortly after diagnosis.6
These data are important as they suggest
preventing deterioration in lung structure and lung
function requires targeted interventions towards
improving respiratory health and nutrition as soon
as possible after diagnosis, with monitoring of
outcomes during the preschool years before
pulmonary disease has become extensive.
We have developed a clinically based respiratory
early surveillance programme for the detection of
lung disease in infants and young children with CF
that involves measurement of pulmonary inﬂam-
mation and infection commencing soon after
diagnosis in infants, usually prior to the develop-
ment of symptoms. As improved nutrition is
considered to be associated with better long-term
outcomes in CF, and is the major proven beneﬁt
arising from newborn screening programmes, we
aimed to describe the longitudinal course of
pulmonary inﬂammation from diagnosis following
newborn screening over the ﬁrst 3 years of life and
its relationship to the clinically relevant outcome of
nutritional status. Speciﬁcally, we hypothesised
that pulmonary inﬂammation in infants and young
children with CF would be associated with lower
body mass index (BMI).
METHODS
Subjects
Infants and young children with CF were recruited
from the CF clinic of the Princess Margaret
Hospital for Children, Perth where an established
newborn screening programme has existed since
2000.7 Brieﬂy, this involves the measurement of
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Cystic fibrosis
immunoreactive trypsinogen from a heel prick test performed in
the ﬁrst 48e72 h of life.7 Those with immunoreactive trypsin-
ogen >99th centile undergo cystic ﬁbrosis transmembrane
regulator gene mutation analysis. Infants are diagnosed with CF
if they are found to be homozygous (or compound heterozy-
gous) for known disease-producing mutations in the CF gene.
Infants with one CF-associated gene are referred for sweat
testing. Infants were included in the study if they were diag-
nosed with CF after 2000 by newborn screening, and/or had
a positive sweat test. Infants with an early clinical diagnosis
(<4 weeks) were also included. Infants were assessed shortly
after diagnosis, then around the time of their ﬁrst birthday and
annually thereafter at 2 and 3 years of age. Each visit involved
assessment of clinical and nutritional status and bronchoalveolar
lavage (BAL). Clinic-recommended policy is for children to use
amoxicillin clavulanate as antistaphylococcal prophylaxis during
the ﬁrst 2 years of life.
The surveillance programme was approved by the research
ethics committee of The Princess Margaret Hospital for Chil-
dren, Perth. Written consent was obtained from the parents of
all participating subjects for use of clinical data and use of excess
BAL and blood samples for research.
Clinical and nutritional data
Weight and crowneheel length were measured on the day of
testing and expressed as weight, height and BMI z-scores using
international growth reference data.8 A physical examination
was performed by a clinician prior to bronchoscopy and BAL.
Mode of presentation, genotype, current respiratory symptoms,
antibiotic use since the previous assessment and all available
microbiology results were reviewed and recorded.
Bronchoalveolar lavage
Flexible bronchoscopy was performed under general anaesthesia
as previously described5 6 with a ﬁbre-optic video-bronchoscope
(Olympus XP160F) via an endotracheal tube or laryngeal mask
as appropriate. Suction was not performed until the tip of the
bronchoscope was past the carina. The BAL involved the
instillation of 1 ml/kg of sterile normal saline per aliquot and
was retrieved using low pressure suction. Three lavages were
performed in the right middle lobe, and one in the lingula or
most effected lobe on chest CT. The ﬁrst sample from each side
was sent for microbiological assessment, while the second and
third samples from the right side were pooled and analysed for
inﬂammatory markers following centrifugation for 5 min at
1500 rpm. The cell pellet was washed if required, resuspended in
1 ml of phosphate-buffered saline (PBS) and cell counts were
conducted. A blinded observer then counted 300 cells and the
proportion and number of neutrophils were recorded.9
Analysis of inﬂammatorymediators interleukin 1b (IL-1b), IL-6
and tumour necrosis factor a (TNFa) was conducted using
a standard cytometric bead array human inﬂammation kit (BD
Biosciences, San Diego, California, USA) with a working range
between 20 and 5000 pg/ml. Analysis of IL-8 was completed
using an ELISA (BD Opt EIA, BD Biosciences, San Diego, Cali-
fornia, USA) with a working range between 0.01 and 6.40 ng/ml.
Myeloperoxidase (MPO) was measured using an in-house ELISA
as described previously.10
Free neutrophil elastase (NE) activity was assessed using an
activity assay. BAL ﬂuid supernatant was serially diluted 1:2
with Tris buffer in duplicate. Tris buffer was the negative control
and human NE diluted to 25 mg/ml was the standard. The
substrate N-methoxysuccinyl-ala-ala-pro-val p-nitroanilide
(dissolved in N-methyl-2-pyrrolidinone (NMP)) was added to
each well. Activity was read immediately at 405 nm. The plate
was then incubated at 378C in a CO2 incubator and read again at
20, 30 and 40 min. The results were calculated using AssayZap
and the best time point was taken. The lower limit of detection
for this assay was 0.2 mg/ml.
Microbiological samples were cultured on agar plates in the
following manner: blood agar, cytosine lactose electrolyte-deﬁ-
cient agar, and blood agar + ticarcillin (for resistant Pseudomonas
aeruginosa identiﬁcation) then incubated at 358C for 48 h in a CO2
incubator; a PC plate (selective plate for Burkholderia cepacia
complex) was incubated at 358C for 48 h in a CO2 incubator, then
at room temperature for a further 24 h; mannitol salt agar for
Staphylococccus aureuswas incubated at 358C for 48 h in an aerobic
atmosphere; Sabarouds agar (for fungi isolation) was incubated at
358C for 48 h, then at 288C for a further 14 days; Fildes agar (for
Haemophilus isolation) was incubated at 358C for 48 h in an
anaerobic environment (to prevent overgrowth by P aeruginosa).
Bacteria were identiﬁed by colony morphology, Gram stain and
biochemical tests including oxidase and the C390 screening test
speciﬁcally for Pseudomonas. Microbiological results were reported
as positive if at least 104 colony-forming units were identiﬁed per
ml. Respiratory viruses (respiratory syncitial virus (RSV), para-
inﬂuenza 1, 2 and 3, inﬂuenza A and B, adenovirus and cyto-
megalovirus) were detected using direct immunoﬂourescence
and/or rapid viral tissue culture.
Statistical analysis
Spearman rank correlation was used to assess bivariate cross-
sectional associations between each measure of pulmonary
inﬂammation and BMI z-score. For longitudinal analyses, age (in
decimal years) was centred around the mean, and continuous
variables were log10 transformed to approximate the normal
distribution. Due to the small number of samples and incom-
plete follow-up data, linear mixed effects analysis, with random
intercept for subjects, was applied to assess longitudinal asso-
ciations between BMI z-score and measures of pulmonary
inﬂammation. Models were also adjusted for age, gender, anti-
staphylococcal antibiotics and presence of symptoms. Linear
mixed effects modelling was done in Stata version 10.0, and all
other analyses were done through SPSS 15. For the analyses,
values for 50% of the lowest limits of detection were substituted
where pulmonary inﬂammation was undetected in BAL.
RESULTS
Forty-two infants (16 (38.1%) male) were diagnosed with CF
between the inception of newborn screening and February 2006.
This period was chosen to allow for longitudinal data collected
up to the age of w3 years to be included. Thirty-six of these
were diagnosed by newborn screening (at median age 4 weeks)
and six by early clinical diagnosis (all with meconium ileus
diagnosed <4 weeks). Twenty-four (57%) were homozygous and
16 (38%) heterozygous for the Phe508del mutation, respectively.
Thirty-nine (92.9%) infants were pancreatic insufﬁcient. Parent-
reported respiratory symptoms (cough, wheeze or any breathing
difﬁculty) were present at the time of the assessments in 38, 36,
31 and 36%, respectively, of the 36 infants diagnosed by
newborn screening. A total of 40, 77, 63 and 57% of infants,
respectively, were receiving prophylactic antistaphylococcal
antibiotics at assessment.
Nutritional indices
Height was well preserved during the course of the study.
Median weight z-scores were reduced at diagnosis but
increased and normalised during subsequent evaluations. BMI
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z-scores followed a similar pattern to weight z-scores (ﬁgure 1
and table 1).
Association between pulmonary inflammation and BMI z-score
Pulmonary inﬂammation identiﬁed at each assessment is shown
in table 1. Neutrophils were detected in all BAL samples. There
were no obvious trends over time in the proportion of neutrophils
in the BAL total cell population or in the number of neutrophils in
the BAL. IL-1b, IL-6 andMPOwere detected inmost BAL samples
and no obvious trend could be identiﬁed at the different assess-
ments. NE was detected in approximately a third of BAL and less
frequently than IL-8 which was detected in w80% of BAL
(table 1). When detected, levels of NE increased over the ﬁrst
2 years but then fell slightly at the ﬁnal BAL, whereas IL-8
increased throughout the study (table 1 and ﬁgure 2).
Signiﬁcant correlations were seen between the different
indices of neutrophilic inﬂammation: neutrophil number (and
proportion), IL-8, NE and MPO. Thus, the effects of inﬂamma-
tion variables on BMI were examined individually. There was no
obvious correlation between pulmonary inﬂammation and BMI
z-score at any of the individual assessments (correlations shown
for NE and IL-8 in table E1 of the online supplement). In
longitudinal analyses (table 2), log10 neutrophil number, log10
IL-6, log10 IL-8, log10 MPO, log10 IL-1b and log10 TNFa were not
signiﬁcantly associated with reduced BMI z-score, whereas log10
free NE was associated with a lower BMI z-score (p¼0.022). On
average, each log10 increase in NE was associated with a 0.43
(95% CI 0.06 to 0.79) reduction in BMI z-score, as shown in
table 2. Details of the full adjusted mixed effects model for the
association between NE and BMI z-score is shown in table E2 of
the online supplement.
Age (p¼0.01) and treatment with antistaphylococcal antibi-
otic prophylaxis (p¼0.013) had a signiﬁcant positive association
with BMI z-score, whereas gender, genotype and presence of
symptoms were not associated with BMI z-score.
Association between pulmonary infection and BMI z-score
Apart from one infant in whom RSV was isolated, viruses were
not detected in BAL. The known CF airway pathogens, S aureus
and P aeruginosa, were the most commonly detected bacteria in
BAL (table 1). Other organisms detected in the respective BAL
were in the ﬁrst BAL: Escherichia coli (n¼1), Aspergillus fumigata
(n¼1), Haemophilus inﬂuenzae (n¼1), Enterobacter cloacae (n¼4),
Klebsiella spp. (n¼1); in the second BAL: A fumigata (n¼1),
H inﬂuenzae (n¼1), E cloacae (n¼1); in the third BAL: A fumigata
(n¼1), Moraxella catarrhalis (n¼1), Stenotrophomonas maltophilia
(n¼1); in the fourth BAL: E coli (n¼1), A fumigata (n¼1),
H inﬂuenzae (n¼3), Klebsiella spp. (n¼1).
A mixed effects analysis was used to evaluate the inﬂuence of
pulmonary infection (S aureus and P aeruginosa) on BMI z-score
after adjusting for potential confounders (table 3). Infection
with S aureus was associated with a mean reduction of 1.04
z-score for BMI. No association was observed for infection with
P aeruginosa (p¼0.918). Thus, respiratory tract infection with
S aureus identiﬁed in BAL was associated with lower BMI
z-scores after accounting for age, gender and antistaphylococcal
antibiotic prophylaxis.
Infection with either S aureus (mean 0.39; 95% CI 0.12 to 0.66;
p¼0.004) or P aeruginosa (mean 0.78; 95% CI 0.460 to 1.09;
p<0.001) was signiﬁcantly associated with increased log10 free
NE, but treatment with antistaphylococcal antibiotic prophy-
laxis was not (0.021; 95% CI 0.226 to 0.185; p¼0.842).
DISCUSSION
Many countries in Europe and the majority of the USA have
now adopted newborn screening programmes for CF. Improved
nutritional status is an important clinical outcome in CF and is
the most obvious beneﬁt afforded by an early diagnosis from
newborn screening. In the present single-centre study in infants
and young children with CF diagnosed mainly by newborn
screening we have shown that early pulmonary inﬂammation
characterised by free NE and infection with S aureus are asso-
ciated with worse nutritional status in the ﬁrst few years of life,
in the absence of clinically apparent respiratory disease in most
children. This association was evident despite modern CF care
that included an aggressive clinical approach to improving
nutrition, apparent normalisation of nutritional status in the
vast majority of subjects and treatment of any pulmonary
exacerbations. The results of our study are crucial in informing
future clinical practice if further beneﬁts from newborn
screening are to be realised.
Several studies have demonstrated that pulmonary inﬂam-
mation is evident soon after diagnosis in CF, but the longitudinal
nature of our study allowed us to investigate its relationship
with BMI over the ﬁrst 3 years of life. This is important as any
relationship between pulmonary inﬂammation and BMI z-score
is likely to be temporally complex. Assessment of inﬂammation
in the BAL provides a single-time ‘snap-shot’ of the inﬂamma-
tory processes occurring in the lungs. However, BMI provides
a cumulative assessment of nutrition. Thus the lack of correla-
tion between these at single time points is not surprising. BMI
Figure 1 (A) Height, (B) weight and (C) body mass index (BMI) z-scores measured soon after diagnosis and at 1, 2 and 3 years of age. The box and
whiskers represent the median, IQR and range respectively.
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z-scores or percentiles have been shown to be a valid measure of
nutritional status in CF and predict nutritional failure more
sensitively and accurately than conventional anthropometric
measures.11 12 In the post-screening era, where infants generally
maintain normal height in contrast to children diagnosed
following clinical presentation, we believe that BMI z-score can
be used instead of other measures of nutritional status such as
weight-for-height. However, more comprehensive measures of
nutritional status such as measurement of body composition
may provide a better insight into early nutritional status and
should be considered for future studies. In older subjects,
improved nutritional status has been shown to be associated
with improved survival in those with CF.13 In childhood,
increased BMI is associated with better lung function.14 Recent
data from the Wisconsin group identiﬁed that patients with CF
who achieved early growth recovery within 2 years of diagnosis
had fewer cough symptoms, better lung function and better
chest radiograph scores at 6 years of age, whereas growth
patterns between the ages of 2 and 6 years were not associated
with pulmonary measures at age 6.15 Their ﬁnding that beneﬁts
of newborn screening on pulmonary status at 6 years of age
depend on early nutritional outcomes emphasises the need for
comprehensive and aggressive treatment implemented as soon
as possible after diagnosis. Thus, it is likely that improving BMI
during the ﬁrst few years of life could have further signiﬁcant
positive health beneﬁts in later life for those with CF. Although
treating fat malabsorption due to pancreatic insufﬁciency results
in apparent normalisation of nutritional status in the majority,
our study highlights the need to investigate the association
between pulmonary inﬂammation and nutritional status further
in order to ﬁnd new strategies for optimising clinical outcomes.
We measured cytokines, cells and inﬂammatory products
known to be associated with pulmonary disease in CF. We found
that NE was signiﬁcantly associated with a reduction in BMI
Figure 2 (A) Log transformed
interleukin 8 (IL-8; pg/ml) and (B)
neutrophil elastase (ng/ml) measured
soon after diagnosis and at 1, 2 and 3
years of age. The box and whiskers
represent the median, IQR and range,
respectively.
Table 1 Nutrition, inflammation and infection data
Initial assessment
(n[36)
Year 1 assessment
(n[42)
Year 2 assessment
(n[42)
Year 3 assessment
(n[42)
Height (cm) 57 (44 to 73) 78 (67 to 85) 88 (76 to 102) 98 (85 to 107)
Height z-score 0.9 (7.4 to 5.0) 0.1 (3.7 to 2.3) 0.1 (3.1 to 3.9) 0.3 (2.7 to 2.7)
Weight (kg) 4.8 (2.7 to 10.0) 10.7 (7.2 to 14.7) 12.9 (9.4 to 17.5) 15.0 (10.8 to 18.8)
Weight z-score 1.7 (5.6 to 2.3) 0.0 (3.2 to 2.4) 0.1 (2.6 to 2.2) 0.1 (2.8 to 1.6)
BMI 14.7 (10.1 to 18.8) 17.8 (1.6 to 21.0) 16.3 (13.2 to 18.9) 15.7 (13.1 to 17.7)
BMI z-score 1.5 (5.7 to 2.0) 0.5 (3.9 to 2.4) 0.2 (2.9 to 1.6) 0.1 (2.5 to 1.2)
Neutrophils (% of total cell) 25. 2 (4.0 to 76.7) 22.0 (4.3 to 80.3) 17.0 (2.0 to 83.3) 27.3 (2.67 to 87.0)
Neutrophils (3103/ml) 70.6 (2.89 to 394) 78.0 (10.7 to 1510) 44.4 (4.19 to 2210) 124.8 (4.89 to 1460)
No. (%) in whom IL-1b was detected 17 (47.2) 23 (54.8) 19 (45.2) 26 (61.9)
IL-1b (pg/ml) 39.7 (20.5 to 397) 55.3 (28.0 to 2710) 50.1 (20.1 to 151) 44.2 (21.7 to 569)
No. (%) in whom IL-6 was detected 18 (50.0) 22 (52.4) 23 (54.8) 25 (59.5)
IL-6 (pg/ml) 50.0 (20.0 to 88.1) 46.9 (25.1 to 192) 46.4 (11.8 to 5000) 79.6 (19.2 to 1660)
No. (%) in whom IL-8 was detected 30 (83.3) 34 (81.0) 35 (83.3) 36 (90)
IL-8 (pg/ml) 400 (120 to 2845) 490 (120 to 5430) 755 (110 to 66000) 1310 (150 to 22500)
No. (%) in whom TNFa was detected 0 (0) 0 (0) 0 (0) 2 (4.8)
TNFa (pg/ml) Not detected Not detected Not detected 47.7 (38.6 to 56.7)
No. (%) in whom NE was detected 13 (36.1) 8 (19.0) 9 (21.4) 13 (32.5)
NE (ng/ml) 1330 (300 to 11725) 2240 (1090 to 10080) 3115 (250 to 18950) 1935 (240 to 10270)
No. (%) in whom MPO was detected 8 (22.2) 16 (38.1) 20 (47.6) 21 (50.0)
MPO (ng/ml) 420 (48.7 to 2405) 118 (9.1 to 1381) 350.5 (5.4 to 2970) 861 (7.0 to 7536)
No. (%) with any infection (at least 104 CFU/ml) 18 (50) 11 (26.2) 12 (28.6) 16 (38.1)
No. (%) in whom S aureus was detected 9 (25.0) 3 (7.1) 6 (14.3) 7 (17.5)
No. (%) in whom P aeruginosa was detected 3 (8.3) 4 (9.5) 4 (9.5) 4 (10.0)
No. (%) on S aureus prophylaxis 17 (42.5) 31 (73.8) 26 (61.9) 24 (57.1)
Data are presented as the median (range) or number (%). Inflammation data are reported from subjects in whom pulmonary inflammation was detected in broncho-alveolar lavage.
BAL, bronchoalveolar lavage; BMI, body mass index; CFU, colony-forming units; IL, interleukin; MPO, myeloperoxidase; NE, neutrophil elastase; TNF, tumour necrosis factor.
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even though it was detected in a small number of subjects. NE is
a serine protease with broad target speciﬁcity. Free NE indicates
that the antiproteinase mechanisms have been overwhelmed,
exposing proteins associated with the basal lamina, extracellular
matrix and cell-associated glycocalyxses to hydrolysation. We
have shown previously that detection of free NE in the infant
CF airway is associated with bronchiectasis.6 We also identiﬁed
a signiﬁcant association between NE and lower respiratory tract
infection with S aureus. Whether interventions to suppress
pulmonary inﬂammation improve early nutritional status
remains to be determined. Few centres speciﬁcally target the
neutrophil-dominated pulmonary inﬂammation of CF during
the ﬁrst few years of life. A number of non-speciﬁc anti-
inﬂammatory treatments, for example macrolides, or speciﬁc
treatments, such as inhibitors of NE, have been proposed. The
results of the present study inform such potential studies and
suggest that the BMI z-score may be useful as a practical
outcome measure of response to early interventions.
Aggressive treatment of infections, in particular those due to
P aeruginosa, has been shown to decrease pulmonary inﬂamma-
tion.16 We detected this organism in only four children and were
limited in our ability to study such associations. Early detection
and eradication of infection with P aeruginosa has become
routine in many centres irrespective of symptoms. The small
numbers of patients infected with P aeruginosa, the use of
aggressive eradication and the possibility that the generally later
acquisition of P aeruginosa compared with infection with
S aureus were reasons why we were unable to show an associ-
ation between infection with this organism and worse nutri-
tional status in this study. While antipseudomonal strategies are
clearly important, infection with S aureus is more common in
infants, and efforts to treat this organism more aggressively need
to be investigated. We identiﬁed a signiﬁcant association
between early lower respiratory infection with S aureus and
worse BMI z-scores. Intravenous antibiotics in infants are
associated with a reduction in pulmonary inﬂammation
detected on BAL,17 but are not usually recommended for infec-
tion with S aureus in the absence of symptoms. Although it has
become the standard of care in many centres to use orally
administered prophylactic antibiotics against S aureus during the
ﬁrst year or more of life,18 this practice is not universal and its
beneﬁts have not yet been subjected to a systematic randomised
control trial.19 In our study, treatment with antistaphylococcal
antibiotics was associated with signiﬁcantly better BMI, but we
must emphasise that it was not speciﬁcally designed to test this
association. While clinic policy was to use antistaphylococcal
prophylaxis for the ﬁrst 2 years of life, variations in prescribing
these antibiotics were partly determined by the importance
attached to this strategy by treating physicians and the will-
ingness of parents and carers to administer long-term antibiotics
to apparently well children. As we have shown that infection
with S aureus is associated with both pulmonary inﬂammation
and worse nutritional status, speciﬁcally designed studies are
needed to determine whether a more aggressive approach of
prevention, early detection and treatment of infection with this
organism results in improvement in BMI and other clinical
outcomes in the ﬁrst years of life.
Surveillance bronchoscopy with BAL is not routine in CF, and
so many would consider our approach to be rather invasive. As
organisms such as S aureus may be found routinely in the upper
airway even in healthy children without CF, we believe that BAL
is the ‘gold standard’ technique for identifying this organism in
the lower respiratory tract rather than reliance on upper airway
microbiological samples, especially as infection with S aureus can
occur in the absence of symptoms. Accurate and early detection
of infection with S aureus is important, and so our results offer
support for more routine use of BAL in pulmonary surveillance.
Pulmonary inﬂammation can also occur in the absence of clinical
symptoms or signs.20 To our knowledge there is no validated
alternative to performing BAL for the detection of pulmonary
inﬂammation in clinical practice in infants. Despite our more
invasive approach, one limitation of our study is that we were
only able to conduct BAL on a few occasions due to the
requirement for general anaesthesia for this procedure. Thus, we
can only provide a ‘snap-shot’ of the true relationship between
infection, inﬂammation and nutritional status.
We conclude that pulmonary inﬂammation in infants with
CF diagnosed by newborn screening is associated with worse
nutritional status. Aggressive surveillance and controlled
trials of targeted interventions in early life are required to
better understand the relationships between pulmonary
inﬂammation and nutrition. Studies are required to assess
whether such interventions can improve clinical outcomes for
those with CF.
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IL-8 0.18 0.16 0.271 0.50 to 0.14
Data shown represent independent associations for each measure of inflammation with
BMI. Models were adjusted for gender, antistaphylococcal antibiotic prophylaxis, presence
of respiratory symptoms and centred-age squared.
BMI, body mass index; IL, interleukin; MPO, myeloperoxidase; NE, neutrophil elastase; TNF,
tumour necrosis factor.
Table 3 Associations between pulmonary infection and body mass
index (BMI) z-score
Organism
Change in
BMI z-score SE p Value 95% CI
S aureus 1.04 0.31 0.001 1.64 to 0.43
P aeruginosa 0.04 0.36 0.918 0.66 to 0.74
The model was adjusted for gender, antistaphylococcal antibiotic prophylaxis, and
centred-age squared.
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Journal club
Genetic variants and risk of lung cancer in never
smokers
This four-stage study systematically investigated common genetic variations associated with
the risk of developing lung cancer in never smokers. Stage 1 involved a genome-wide
association study at the Mayo Clinic. A total of 331 918 single nucleotide polymorphisms
(SNPs) in 377 caseecontrol matched pairs were analysed. The 44 most signiﬁcant SNPs that
might alter the risk of lung cancer in never smokers were selected. The MD Anderson Cancer
Center and Harvard School of Public Health (n¼735 and 335, respectively) tested these 44
most signiﬁcant SNPs. The SNP rs2352028 (at 13q31.3) was the one most associated with
lung cancer in never smokers. This ﬁnding was repeated in a replication cohort.
For all four studies the combined p value for the association between rs2352028 and lung
cancer in never smokers was 5.943106 (OR 1.46, 95% CI 1.26 to 1.70). 10% of lung cancer
cases in never smokers could be attributed to genetic variation of SNP rs2352028. A gene
expression proﬁle analysis conﬁrmed that the expression of the gene GPC5 was associated
with genotypes of SNPs, with lower expression in high-risk alleles.
This study suggests that genetic variants affecting the expression of the GPC5 gene are
responsible for increasing the risk of lung cancer in never smokers. However, it was concluded
that the sample sizes used did not allow for enough power, and there was inconsistent
adjustment for confounders such as second-hand smoke exposure across the different centres.
GPC5 gene alterations have previously been shown to inﬂuence lung cancer development and
merit further study.
< Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study.
Lancet Oncol 2010;11:321e30.
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